港股異動 | 綠城中國(3900.HK)大漲超8%創15個月新高 2021年超額完成銷售目標
格隆匯1月7日丨綠城中國(3900.HK)拉昇漲超8%,盤中高見13.96港元創15個月新高價,總市值達346億港元。公司2021年總合同銷售金額約3509億元,同比增長約21%。2021年,公司的合同銷售目標是3100億元以上。由此計算,2021年綠城完成了年目標的113.2%。在行業下行背景下,綠城中國銷售力依舊強勁。憑藉穩健的經營策略和前瞻性的佈局,綠城獲多家國際評級機構和券商肯定。近日,花旗銀行將綠城中國上調至“買入”評級,瑞信上調綠城中國評級至“中性”,穆迪維持綠城中國企業家族評級為Ba3,展望“穩定”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.